Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Targeting antigen-presenting cells by anti–PD-1 nanoparticles augments antitumor immunity
Farideh Ordikhani, Mayuko Uehara, Vivek Kasinath, Li Dai, Siawosh K. Eskandari, Baharak Bahmani, Merve Yonar, Jamil R. Azzi, Yousef Haik, Peter T. Sage, George F. Murphy, Nasim Annabi, Tobias Schatton, Indira Guleria, Reza Abdi
Farideh Ordikhani, Mayuko Uehara, Vivek Kasinath, Li Dai, Siawosh K. Eskandari, Baharak Bahmani, Merve Yonar, Jamil R. Azzi, Yousef Haik, Peter T. Sage, George F. Murphy, Nasim Annabi, Tobias Schatton, Indira Guleria, Reza Abdi
View: Text | PDF
Research Article Immunology

Targeting antigen-presenting cells by anti–PD-1 nanoparticles augments antitumor immunity

  • Text
  • PDF
Abstract

Recent studies in cancer research have focused intensely on the antineoplastic effects of immune checkpoint inhibitors. While the development of these inhibitors has progressed successfully, strategies to further improve their efficacy and reduce their toxicity are still needed. We hypothesized that the delivery of anti–PD-1 antibody encapsulated in PLGA nanoparticles (anti–PD-1 NPs) to the spleen would improve the antitumor effect of this agent. Unexpectedly, we found that mice treated with a high dose of anti–PD-1 NPs exhibited significantly higher mortality compared with those treated with free anti–PD-1 antibody, due to the overactivation of T cells. Administration of anti–PD-1 NPs to splenectomized LT-α–/– mice, which lack both lymph nodes and spleen, resulted in a complete reversal of this increased mortality and revealed the importance of secondary lymphoid tissues in mediating anti–PD-1–associated toxicity. Attenuation of the anti–PD-1 NPs dosage prevented toxicity and significantly improved its antitumor effect in the B16-F10 murine melanoma model. Furthermore, we found that anti–PD-1 NPs undergo internalization by DCs in the spleen, leading to their maturation and the subsequent activation of T cells. Our findings provide important clues that can lead to the development of strategies to enhance the efficacy of immune checkpoint inhibitors.

Authors

Farideh Ordikhani, Mayuko Uehara, Vivek Kasinath, Li Dai, Siawosh K. Eskandari, Baharak Bahmani, Merve Yonar, Jamil R. Azzi, Yousef Haik, Peter T. Sage, George F. Murphy, Nasim Annabi, Tobias Schatton, Indira Guleria, Reza Abdi

×

Figure 2

In vitro and in vivo distribution and retention of NPs in melanoma tumor-bearing mice.

Options: View larger image (or click on image) Download as PowerPoint
In vitro and in vivo distribution and retention of NPs in melanoma tumor...
(A) Representative images of the distribution of IR800 NPs in a melanoma tumor–bearing mouse from 1 minute to 24 hr showing accumulation of NPs at the tumor site. By the 24-hr mark, the NPs are no longer observed. (B) Representative images and quantitative fluorescence intensities of tumors and spleens as calculated from ex vivo images 0 hr (before injection), 6 hr, and 24 hr after administration. The data shown are mean ± SEM (n = 3–4 mice/group). (C) Micrograph of splenocytes illustrating localization of NPs within the cytoplasm following 3 hr of incubation in vitro with NPs. Intracellular fluorescence intensities were detected by confocal microscopy. (D) Uptake of CF660 NPs by APCs in the spleens harvested from melanoma tumor–bearing mice 24 hr following injection, as measured by flow cytometry. Data represent mean ± SEM (n = 3 mice/group). Statistical significance was calculated using 1-way ANOVA (B) and 2-tailed Student’s t test (D). *P<0.05; **P<0.01; ***P<0.005.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts